Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 4/20 | 0.34 |
| ▸ | PPARA | Q07869 | 4/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57115 | 0.93 | ATM (0.39) | BTN3A1ELANEPRTN3MEN1KMT2A | |
| SCHEMBL56408 | 0.92 | BTN3A1 (0.37) | BTN3A1ELANEPRTN3MEN1MAPT | |
| SCHEMBL57135 | 0.90 | MAPT (0.41) | BTN3A1ELANEPRTN3MAPTKMT2A | |
| SCHEMBL56935 | 0.89 | ALDH1A1 (0.41) | BTN3A1ELANEPRTN3PPARGPPARA | |
| SCHEMBL56920 | 0.88 | MMP2 (0.37) | BTN3A1ELANEPRTN3PPARGPPARA | |
| SCHEMBL56614 | 0.88 | MAOB (0.37) | BTN3A1ELANEPRTN3MEN1MAPT | |
| SCHEMBL56739 | 0.88 | GAA (0.38) | MEN1MAPTKMT2A | |
| SCHEMBL57805 | 0.86 | KYNU (0.35) | ELANEPRTN3 | |
| SCHEMBL56758 | 0.85 | ALDH1A1 (0.39) | BTN3A1MEN1MAPTKMT2A | |
| SCHEMBL57868 | 0.84 | L3MBTL1 (0.37) | BTN3A1ELANEPRTN3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | claimed |
| US-8129557-B2 | Phosphonic acid diester derivative and method for producing thereof | Nagai, Kazuhiro (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | HIRATAKE, GOU (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | PPA1, G6PD, PHOSPHO1 | TP53 1700/4885BTN3A1 4679/4885ELANE 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.